N/A
Manufactured by UroGen Pharma, Inc.
4,566 FDA adverse event reports analyzed
Last updated: 2026-04-15
MITOMYCIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by UroGen Pharma, Inc.. The most commonly reported adverse reactions for MITOMYCIN include OFF LABEL USE, NAUSEA, DIARRHOEA, FATIGUE, THROMBOCYTOPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MITOMYCIN.
Out of 3,064 classified reports for MITOMYCIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 4,566 FDA FAERS reports that mention MITOMYCIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, NAUSEA, DIARRHOEA, FATIGUE, THROMBOCYTOPENIA, DRUG INEFFECTIVE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list UroGen Pharma, Inc. in connection with MITOMYCIN. Always verify the specific product and NDC with your pharmacist.